IP Library Granted Patent US 11,375,717
Granted Patent B2
US 11,375,717 · App. 16/984,898 · Granted Jul 5, 2022

Combinations of acaricides and insect growth regulators for control of fleas without emesis in animals

Inventors: Douglas Hepler (Greensboro, NC); Roland Johnson (Greensboro, NC); Gail Dempsey (Greensboro, NC); Michael Kelly (Greensboro, NC)
Assignee: Piedmont Animal Health Inc.
A01N43/22A01N47/34A61K9/0056A61K9/2009A61K9/2054A61K9/485A61K9/4866A61K31/17A61K31/7048A01N2300/00A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,375,717
App. No.
16/984,898
Granted
Jul 5, 2022
Kind
B2
Abstract

A single-dose oral formulation of spinosad and lufenuron and methods for its use in the extended control of a flea infestation on a domestic animal such as a dog without emesis.

Claims (11)

1. A method of controlling a flea infestation on an animal, comprising administering to the animal an effective amount of a single-dose oral formulation comprising spinosad, lufenuron, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, and optionally an artificial flavor, wherein the formulation is suitable for oral administration once every 30 days at a dose of at least about 20 mg of spinosad per kg of body weight of the animal, and about 10 mg of lufenuron per kg of body weight of the animal.

2. The method of claim 1 , wherein the animal is a dog and the formulation has greater than about 75, 90 or 95% residual efficacy at 30 days post-administration.

3. A method of controlling a flea infestation on an animal, comprising administering to the animal an effective amount of a single-dose oral formulation per month, the formulation comprising spinosad and lufenuron at a dose of at least about 20 mg of spinosad per kg of body weight of the animal, and about 10 mg of lufenuron per kg of body weight of the animal.

4. The method of claim 3 , wherein the animal is a cat.

5. The method of claim 3 , wherein the animal is a dog.

6. The method of claim 3 , wherein the animal is a domesticated dog.

7. The method of claim 3 , wherein the formulation is a tablet or capsule.

8. The method of claim 3 , wherein the formulation has greater than 75% residual efficacy at 30 days post-administration.

9. The method of claim 3 , wherein the formulation has greater than 90% residual efficacy at 30 days post-administration.

10. The method of claim 3 , wherein the formulation has greater than 95% residual efficacy at 30 days post-administration.

11. The method of claim 3 , wherein the single-dose oral formulation is administered about every 30 days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: PIEDMONT ANIMAL HEALTH LLC
To: DECHRA VETERINARY PRODUCTS, LLC
Reel/Frame 061769/0452 →
Continuity (3)
Division 15938861 · Mar 28, 2018
Provisional Application 62477886 · Mar 28, 2017
Related Publication 20200359624A1 · Nov 19, 2020